Skip to main content
S&P 5007,520.93-0.38%DOW52,231.89-0.30%NASDAQ25,065.88-0.74%BTC$73,824.00-0.55%ETH$2,053.89-1.84%GOLD$4,050.70+0.51%OIL$87.14+1.28%
Smart Investors Daily
SID Premium
QG

NYSE · QGEN

Qiagen N.V.

Healthcare · Medical - Diagnostics & Research

$50.51

Down-$0.04 (-0.08%)

Updated Nov 11, 2026, 1:26 PM

SID Score

6.4/10

Composite research score

Smart Money

58/100

Neutral

Market cap
9.85B
P/E ratio
24.3
Dividend yield
2.99%
52-week range
$32.53 – $57.82
Volume
5.32M
Avg. volume
1.17M

Price performance · QGEN

QGEN price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 10, 2026

QGEN closed at $50.51 after 21 trading sessions, up 11.16% for the selected period.

Last close
$50.51
Period change
+11.16%
Period low
$45.44
Period high
$50.86
Daily close
View OHLC price history
QGEN OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 10, 2026$50.47$50.55$50.20$50.515.32M
Nov 9, 2026$50.57$50.65$50.505$50.555.39M
Nov 6, 2026$50.42$50.50$50.264$50.333.39M
Nov 5, 2026$50.715$50.97$50.65$50.864.63M
Nov 4, 2026$50.76$50.88$50.65$50.833.23M
Nov 3, 2026$50.41$50.42$50.235$50.387.35M
Nov 2, 2026$50.50$50.50$50.305$50.353.57M
Oct 30, 2026$50.35$50.39$50.07$50.224.17M
Oct 29, 2026$50.18$50.41$50.10$50.343.55M
Oct 28, 2026$50.25$50.38$50.15$50.334.53M
Oct 27, 2026$50.32$50.39$50.17$50.174.26M
Oct 26, 2026$50.42$50.53$50.30$50.374.11M
Oct 23, 2026$50.38$50.445$50.325$50.397.14M
Oct 22, 2026$50.50$50.52$49.90$50.2240.83M
Oct 21, 2026$48.12$50.25$46.89$50.0012.53M
Oct 20, 2026$46.97$50.82$46.62$48.9010.13M
Oct 19, 2026$46.18$46.915$45.84$46.552.16M
Oct 16, 2026$46.59$46.75$45.965$46.132M
Oct 15, 2026$45.96$46.485$45.595$46.171.31M
Oct 14, 2026$45.885$46.3677$45.47$45.561.63M
Oct 13, 2026$45.77$45.79$44.97$45.441.44M

Latest QGEN news

The latest Smart Investors Daily articles mentioning QGEN.

Stock researchCompany · Overview

QGEN research

Overview

Company profile and research snapshot.

Company profile

Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$53.00
Implied upside
—
Analysts
—
QGEN recent ratings
DateFirmRatingTarget
Oct 28, 2026BarclaysEqual-Weight—
Oct 26, 2026CitigroupNeutral—
Oct 22, 2026JP MorganNeutral—
Oct 22, 2026BairdOutperform—
Oct 14, 2026JP MorganOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 6, 2026

Qiagen (QGEN) Stock May Be Fully Priced As Sequencing Project Expands

Qiagen has delivered a 35.3% gain over the past three years, and recent headlines around genomics partnerships and sequencing markets keep the story in focus. The question now is whether that share price trajectory lines up with what the company’s cash flows can reasonably support. With a 35.3% return over three years, Qiagen now asks investors to judge whether that run is backed by the cash its business can generate over time. New projects in areas such as precision medicine, clinical...

Yahoo · Nov 6, 2026

QIAGEN Shareholders Overwhelmingly Approve Jonathan M. Pratt as Managing Director

VENLO, Netherlands, November 06, 2026--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that shareholders overwhelmingly approved the appointment of Jonathan M. Pratt as a Managing Director and member of the QIAGEN Managing Board at an Extraordinary General Meeting of Shareholders.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By